Muscarinic Acetylcholine Receptor M2 (CHRM2) – Drugs In Development, 2021

Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 10 molecules. The latest report Muscarinic Acetylcholine Receptor M2 – Drugs In Development, 2021, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 5 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Respiratory, Cardiovascular, Dermatology, Genetic Disorders and Undisclosed which include indications Alzheimer's Disease, Obstructive Sleep Apnea, Overactive Bladder, Parkinson's Disease, Urinary Incontinence, Angelman Syndrome, Axillary Hyperhidrosis, Depression, Fragile X Syndrome, Infantile Spasm (West Syndrome), Psychosis, Rett Syndrome, Schizophrenia, Stroke, Tuberous Sclerosis and Unspecified Rare Disease.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)

– The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2) Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Anavex Life Sciences Corp

Apnimed Inc

Dermavant Sciences Inc

FemmePharma Global Healthcare Inc

Karuna Therapeutics Inc

Sinsin Pharmaceutical Co Ltd

TheraVida Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

Apnimed Inc

Dermavant Sciences Inc

FemmePharma Global Healthcare Inc

Karuna Therapeutics Inc

Sinsin Pharmaceutical Co Ltd

TheraVida Inc

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles

(atomoxetine + oxybutynin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxybutynin + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxybutynin + reboxetine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(pilocarpine + tolterodine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blarcamesine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones

Featured News & Press Releases

Jun 23, 2021: Karuna Therapeutics announces results from phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers

Jun 21, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) biomarker correlated with efficacy endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome

Jun 14, 2021: Anavex Life Sciences reports new publication in medical journal elucidating the mechanism of ANAVEX2-73 (blarcamesine) related to the treatment of Alzheimer's Disease

Jun 08, 2021: Anavex Life Sciences announces exceeding of enrollment target for the precision medicine ANAVEX2-73 (blarcamesine) phase 2b/3 clinical trial in patients with Alzheimer’s Disease

Jun 03, 2021: Anavex Life Sciences announces Notice of allowance for U.S. patent application ANAVEX2-73 (blarcamesine) for the treatment of cardiac dysfunctions

May 17, 2021: New data presented at American Thoracic Society Meeting reinforces the potential of an oral drug combination therapy for the treatment of obstructive sleep apnea

Apr 12, 2021: Anavex Life Sciences reports the results of review by the Independent Data Safety Monitoring Board for its phase 2/3 trials of ANAVEX2-73 in patients with Rett syndrome

Mar 31, 2021: Anavex Life Sciences reports data review by the Independent Data Safety Monitoring board for its phase 2b/3 clinical trial of ANAVEX2-73 in patients with Alzheimer’s Disease

Mar 25, 2021: Apnimed closes Series B financing to advance once-daily oral medication for Obstructive Sleep Apnea (OSA)

Mar 16, 2021: Anavex Life Sciences reports ANAVEX2-73 (blarcamesine) featured as a disease-modifying small molecule in phase 3 clinical trials in a new publication in medical journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

Feb 24, 2021: Karuna Therapeutics anounces New England Journal of Medicine publication of data from EMERGENT-1 phase 2 trial evaluating KarXT in Schizophrenia

Jan 20, 2021: Apnimed doses first patient in obstructive sleep apnea drug trial

Jan 11, 2021: Anavex Life Sciences receives Michael J. Fox Foundation grant for clinical study of ANAVEX2-73 (blarcamesine) in people with Parkinson’s Disease

Dec 21, 2020: Anavex Life Sciences announces webinar on Rett syndrome and ANAVEX2-73 (Blarcamesine) phase 2 data hosted by Ladenburg Thalmann & Co.

Dec 15, 2020: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) meets primary and secondary endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Anavex Life Sciences Corp, 2021

Pipeline by Apnimed Inc, 2021

Pipeline by Dermavant Sciences Inc, 2021

Pipeline by FemmePharma Global Healthcare Inc, 2021

Pipeline by Karuna Therapeutics Inc, 2021

Pipeline by Sinsin Pharmaceutical Co Ltd, 2021

Pipeline by TheraVida Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports